- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tevogen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Tevogen Inc.: Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements | 82 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and... ► Artikel lesen | |
| 18.09. | XFRA G280: WIEDERAUFNAHME/RESUMPTION | 255 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 10.09. | Tevogen Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.08. | Tevogen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.08. | Tevogen Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.07. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | Tevogen Bio becomes Tevogen Inc. | 5 | Seeking Alpha | ||
| TEVOGEN Aktie jetzt für 0€ handeln | |||||
| 29.07. | Tevogen Bio Holdings Inc. Becomes Tevogen Inc. | 42 | GlobeNewswire (Europe) | WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval... ► Artikel lesen | |
| 14.07. | Tevogen Bio Inc: Tevogen Bio Announces 2026 Annual Meeting of Stockholders | 1 | GlobeNewswire (USA) | ||
| 10.07. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.06. | Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative | 672 | GlobeNewswire (Europe) | William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 28.05. | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | 726 | GlobeNewswire (Europe) | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| 21.05. | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 566 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 20.05. | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| 18.05. | Tevogen reports reduced operating losses in 2025 and Q1 2026 | 1 | Investing.com | ||
| 18.05. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 220 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 15.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 371 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 30.04. | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,405 | +5,80 % | Qiagen-Aktie: Was die Spuren im Labor verraten - Warren Wise Podcast | Ein verlässliches Geschäft mit einer Zukunftsgeschichte, die Fragen aufwirft. Qiagen liefert den ersten Handgriff vieler molekularer Untersuchungen: Das Unternehmen löst Erbgut aus Blut, Gewebe oder... ► Artikel lesen | |
| VALNEVA | 2,537 | -0,04 % | Valneva BEGEISTERT Anleger: Meine brandneue Prognose ändert einfach alles - Das müssen Sie am Montag wissen! | ||
| AMGEN | 358,40 | +0,11 % | AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot | ||
| NOVAVAX | 9,230 | -0,65 % | Novavax Inc mit PAUKENSCHLAG: Droht die Aktie jetzt der nächste Absturz? - Jetzt unbedingt lesen! | ||
| REGENERON PHARMACEUTICALS | 648,50 | -0,72 % | Sanofi und Regeneron erweitern Allianz in Milliardendeal | DJ Sanofi und Regeneron erweitern Allianz in Milliardendeal
Von Adria Calatayud
DOW JONES--Sanofi und Regeneron Pharmaceuticals weiten ihre Kooperation zur gemeinsamen Entwicklung und Vermarktung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,330 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,902 | -0,99 % | H.C. Wainwright raises Ocugen stock price target on Bahamas approval | ||
| INOVIO PHARMACEUTICALS | 1,067 | +3,09 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,420 | +0,93 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | -0,90 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,98 | +0,39 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress | Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease
SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,520 | -0,13 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,200 | -2,31 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 58,72 | +3,02 % | Biotech-Aktien vor dem Datentest: Morgan Stanley setzt auf Biotech-Moonshots: Argenx, Arrowhead, Incyte und Sana vor wichtigen Datentests | Vier Biotech-Unternehmen stehen vor wichtigen klinischen Bewährungsproben. Morgan Stanley sieht bei Argenx, Arrowhead, Incyte und Sana Programme mit hohem wirtschaftlichem Potenzial, deren weiterer... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,500 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen |
Das Unternehmen TEVOGEN INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,480 Euro und damit -1,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN INC finden Sie auf Wallstreet Online.